Tiotropium in the treatment of chronic obstructive pulmonary disease health technology assessment
Neyt M, Van den Bruel A, Gailly J, Thiry N, Devriese S
Record ID 32010001227
English
Authors' recommendations:
Long-acting bronchodilators are recommended in patients who remain symptomatic despite adequate treatment with short-acting bronchodilators. Nevertheless, guidelines do not recommend a specific long-acting bronchodilator. Based on a systematic review of the literature, tiotropium is not superior on clinically relevant outcomes than salmeterol. In addition, tiotropium is more expensive by which the cost-effectiveness balance for this drug is unfavourable. In conclusion, tiotropium has its intrinsic merits but is currently too expensive from a medical and payer’s perspective.
Details
Project Status:
Completed
URL for project:
http://kce.fgov.be/publication/report/tiotropium-in-the-treatment-of-chronic-obstructive-pulmonary-disease-health-techn
Year Published:
2009
URL for published report:
http://kce.fgov.be/publication/report/tiotropium-in-the-treatment-of-chronic-obstructive-pulmonary-disease-health-techn
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Belgium
MeSH Terms
- Meta-Analysis as Topic
- Pulmonary Disease, Chronic Obstructive
- Scopolamine Derivatives
Contact
Organisation Name:
Belgian Health Care Knowledge Centre
Contact Address:
Administrative Centre Botanique, Doorbuilding (10th floor), Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium tel: +32 2 287 33 88 fax: +32 2 287 33 85
Contact Name:
info@kce.fgov.be
Contact Email:
info@kce.fgov.be
Copyright:
Belgian Health Care Knowledge Centre (KCE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.